Immune Checkpoint Inhibitors Boost Efficacy of Standard Chemotherapy in Stage 3 Colon Cancer, Study Shows
In a groundbreaking advancement presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, researchers from Dana-Farber Cancer ...
